Vir Biotechnology, Inc. (VIR) FY2026 YTD Q2 Statement of Cash Flows
2026-01-01 to 2026-06-30
Statement of Cash Flows
2026-01-01 to 2026-06-30
Swipe to see the full flow
Chart details
Vir Biotechnology, Inc. cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026
Cash flows for Jan 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2025. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.
- Beginning cash on Dec 31, 2025
- 241,070,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
- Operating activities
- negative 9,060,000 US dollars. Net cash used.
- Net income (loss)
- negative 45,615,000 US dollars
- Depreciation and amortization
- 5,613,000 US dollars
- Amortization of premiums on investments, net
- 716,000 US dollars
- Noncash lease expense
- 2,707,000 US dollars
- Change in fair value of equity investments
- 1,893,000 US dollars
- Change in estimated fair value of contingent consideration
- 240,000 US dollars
- Payment of contingent consideration in excess of acquisition date fair value
- 0 US dollars
- Stock-based compensation
- 24,478,000 US dollars
- Non-cash restructuring, long-lived assets impairment and related charges
- 0 US dollars
- Other non-cash items, net
- 123,000 US dollars
- Prepaid expenses and other current assets
- 6,059,000 US dollars
- Other assets
- 53,000 US dollars
- Accounts payable
- 8,083,000 US dollars
- Accrued liabilities and other liabilities
- negative 8,831,000 US dollars
- Operating lease liabilities
- negative 4,579,000 US dollars
- Investing activities
- negative 185,307,000 US dollars. Net cash used.
- Proceeds from sale of equipment
- 0 US dollars
- Purchases of long-lived assets
- negative 422,000 US dollars
- Purchases of investments
- negative 510,473,000 US dollars
- Maturities and sales of investments
- 325,588,000 US dollars
- Financing activities
- 240,899,000 US dollars. Net cash provided.
- Proceeds from exercise of stock options
- 1,614,000 US dollars
- Proceeds from issuance of common stock under ESPP
- 1,356,000 US dollars
- Issuance of common stock - Astellas
- 75,724,000 US dollars
- Issuance of common stock - Public Offering
- 162,205,000 US dollars
- Other financing activities
- 0 US dollars
- Operating adjustment reconciliation
- 59,025,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
- financing gross reconciliation
- 240,899,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
- investing gross reconciliation
- 510,895,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
- Exchange-rate effect
- 0 US dollars
- Ending cash on Jun 30, 2026
- 287,602,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
- Cash sources and uses
- 481,969,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
- Net cash change
- 46,532,000 US dollars. Ending cash minus beginning cash.
- Cash flow / Net income
- Not meaningful. Operating cash flow divided by reconciliation net income for the same period. The ratio is not meaningful when net income is zero or negative.
- Operating cash flow
- negative 9,060,000 US dollars. Operating cash flow used in the free cash flow calculation.
- Cash purchases of property, plant and equipment
- 422,000 US dollars. These cash purchases are already included in investing activities above.
- Free cash flow
- negative 9,482,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.
Chart connections
- Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
- Financing contributions meet at a reconciliation junction before connecting to the net cash total.
- Investing contributions meet at a reconciliation junction before connecting to the net cash total.
- Operating reconciliation adjustments are not all independent cash receipts.
- Net loss −$45.62M + net operating adjustments $36.56M = operating cash −$9.06M. The loss reduces the earnings basis of the reconciliation; it is not a cash payment. The signed loss remains a deduction at the operating reconciliation junction.
- Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
- The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
- Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: negative 9,060,000 US dollars minus 422,000 US dollars equals negative 9,482,000 US dollars.
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG
Product waitlist
Health Check and Teardown for your own company
A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!